[{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclica \/ Arctoris","highestDevelopmentStatusID":"1","companyTruncated":"Cyclica \/ Arctoris"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest BioEnergy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Solarvest BioEnergy","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma \/ Solarvest BioEnergy"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydrohonokiol-B","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Avicanna \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avicanna \/ Inapplicable"},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Raya Therapeutic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Raya Therapeutic \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Raya Therapeutic \/ Argenx"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sunshine Biopharma \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Bucillamine is a potent antioxidant and anti-inflammatory, small molecule drug candidate. It is being evaluated for the treatment of nerve agent induced brain injury seizure.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 16, 2024

                          Lead Product(s) : Bucillamine,Acetylcysteine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration aims to focus on testing combinations of Raya's pipeline of targeted small molecules with a potentially complementary product from argenx.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 07, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Argenx

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The agreement aims to evaluate Bucillamine, a significantly more effective antioxidant than n-acetylcysteine, as a potential treatment for nerve agent exposure.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 17, 2023

                          Lead Product(s) : Bucillamine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Defence R&D Canada

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimers and other neurodegenerative diseases...

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 23, 2022

                          Lead Product(s) : Cyclosporine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Arctoris

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Oral administration of cannabinoids is the most convenient route for non-invasive drug delivery. Avicanna intends to conduct further pre-clinical studies in the coming months in order to formalize this provisional application and will incorporate the tec...

                          Product Name : re+PLAY

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 12, 2021

                          Lead Product(s) : Cannabinoid

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration for treatment of neurodegenerative disorders.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 10, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The PCT application demonstrate cannabinoid compound inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection also can be used to promote neurite outgrowth, signifying the potential to enhance neuronal function.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 11, 2021

                          Lead Product(s) : Cannabinoid

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BetterLife has filed patent protection on the newest compound to enter its pipeline, dihydrohonokiol-B (“TD-010”). Specifically, BetterLife has filed for patent protection for the use of TD-010 as a treatment for sedative, hypnotic, or anxiolytic us...

                          Product Name : TD-010

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 02, 2021

                          Lead Product(s) : Dihydrohonokiol-B

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares to Solarvest, which will enable Solarvest to fund the CBD Research Project.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 02, 2020

                          Lead Product(s) : Cannabinoid

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Solarvest BioEnergy

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank